Acorda Therapeutics (ACOR) Tops Q4 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
MLV & Co. Starts Acorda Therapeutics, Inc. (ACOR) at Buy
February 12, 2015 8:33 AM ESTMLV & Co. initiated coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Buy rating and a price target of $58.00.
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click... More
